Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 7,500 Shares of Stock

Key Points

• Insider sale: Director Anne Lesage disclosed selling shares around April 22–23, including a reported sale of 7,500 shares at an average of $30.05 (≈$225,375), leaving her with 56,450 shares — an ~11.73% reduction in her position.
• Market and earnings update: PHVS shares traded up about 4.5% to $28.52, the company has a market cap of ~$1.87B, and it reported a quarterly EPS of ($0.84) that missed estimates; analysts’ consensus is a "Moderate Buy" with an average target of $42.73.
• Business focus: Pharvaris is a clinical-stage biopharmaceutical developing oral plasma kallikrein inhibitors for hereditary angioedema, with its lead candidate PHA121 advancing in trials.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anne Lesage sold 7,500 shares of the company's stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $30.05, for a total transaction of $225,375.00. Following the completion of the transaction, the insider directly owned 56,450 shares of the company's stock, valued at $1,696,322.50. This represents a 11.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Anne Lesage also recently made the following trade(s):

• On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $210,350.00.
• On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.

Pharvaris Trading Up 4.5%

Pharvaris stock traded up $1.23 during mid-day trading on Friday, hitting $28.52. The stock had a trading volume of 114,035 shares, compared to its average volume of 172,104. The firm has a market capitalization of $1.87 billion, a P/E ratio of -8.49 and a beta of -2.58. The firm's 50 day moving average is $27.39 and its 200 day moving average is $25.80. Pharvaris N.V. has a one year low of $14.59 and a one year high of $30.24.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.15). As a group, equities research analysts forecast that Pharvaris N.V. will post -3.19 earnings per share for the current year.

Institutional Trading of Pharvaris

Several hedge funds have recently made changes to their positions in PHVS. GF Fund Management CO. LTD. purchased a new stake in Pharvaris in the 4th quarter worth about $35,000. Barclays PLC purchased a new stake in Pharvaris in the 4th quarter worth about $77,000. China Universal Asset Management Co. Ltd. purchased a new stake in Pharvaris in the 3rd quarter worth about $75,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Pharvaris in the 4th quarter worth about $86,000. Finally, JPMorgan Chase & Co. raised its position in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after purchasing an additional 783 shares during the period.

Analysts Set New Price Targets

Several analysts have commented on PHVS shares. Citigroup reiterated a "buy" rating on shares of Pharvaris in a research note on Wednesday, April 15th. Wolfe Research assumed coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an "outperform" rating and a $42.00 price target on the stock. Wall Street Zen cut shares of Pharvaris from a "sell" rating to a "strong sell" rating in a research report on Monday, April 13th. Royal Bank Of Canada decreased their target price on shares of Pharvaris from $52.00 to $51.00 and set an "outperform" rating on the stock in a research report on Monday, April 6th. Finally, HC Wainwright restated a "buy" rating and set a $60.00 target price on shares of Pharvaris in a research report on Tuesday, March 3rd. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pharvaris currently has an average rating of "Moderate Buy" and a consensus price target of $42.73.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.